search
Back to results

Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

Primary Purpose

Chronic Myeloproliferative Disorders, Leukemia, Lymphoma

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
anti-thymocyte globulin
sargramostim
therapeutic allogeneic lymphocytes
busulfan
fludarabine phosphate
methotrexate
tacrolimus
nonmyeloablative allogeneic hematopoietic stem cell transplantation
peripheral blood stem cell transplantation
Sponsored by
UNC Lineberger Comprehensive Cancer Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Myeloproliferative Disorders focused on measuring adult acute myeloid leukemia with 11q23 (MLL) abnormalities, adult acute myeloid leukemia with inv(16)(p13;q22), adult acute myeloid leukemia with t(15;17)(q22;q12), adult acute myeloid leukemia with t(16;16)(p13;q22), adult acute myeloid leukemia with t(8;21)(q22;q22), prolymphocytic leukemia, accelerated phase chronic myelogenous leukemia, adult acute lymphoblastic leukemia in remission, adult acute myeloid leukemia in remission, blastic phase chronic myelogenous leukemia, childhood acute lymphoblastic leukemia in remission, childhood acute myeloid leukemia in remission, childhood chronic myelogenous leukemia, chronic phase chronic myelogenous leukemia, de novo myelodysplastic syndromes, extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue, nodal marginal zone B-cell lymphoma, noncontiguous stage II adult Burkitt lymphoma, noncontiguous stage II adult diffuse large cell lymphoma, noncontiguous stage II adult diffuse mixed cell lymphoma, noncontiguous stage II adult diffuse small cleaved cell lymphoma, noncontiguous stage II adult immunoblastic large cell lymphoma, noncontiguous stage II adult lymphoblastic lymphoma, noncontiguous stage II grade 1 follicular lymphoma, noncontiguous stage II grade 2 follicular lymphoma, noncontiguous stage II grade 3 follicular lymphoma, noncontiguous stage II mantle cell lymphoma, noncontiguous stage II marginal zone lymphoma, noncontiguous stage II small lymphocytic lymphoma, previously treated myelodysplastic syndromes, recurrent adult acute lymphoblastic leukemia, recurrent adult Burkitt lymphoma, recurrent adult Hodgkin lymphoma, recurrent adult diffuse large cell lymphoma, recurrent adult diffuse mixed cell lymphoma, recurrent adult diffuse small cleaved cell lymphoma, recurrent adult immunoblastic large cell lymphoma, recurrent adult lymphoblastic lymphoma, recurrent adult acute myeloid leukemia, recurrent childhood acute myeloid leukemia, recurrent/refractory childhood Hodgkin lymphoma, recurrent childhood acute lymphoblastic leukemia, recurrent childhood large cell lymphoma, recurrent childhood lymphoblastic lymphoma, recurrent childhood small noncleaved cell lymphoma, recurrent cutaneous T-cell non-Hodgkin lymphoma, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, recurrent mycosis fungoides/Sezary syndrome, recurrent small lymphocytic lymphoma, refractory chronic lymphocytic leukemia, refractory multiple myeloma, relapsing chronic myelogenous leukemia, secondary acute myeloid leukemia, secondary myelodysplastic syndromes, splenic marginal zone lymphoma, stage I multiple myeloma, stage II multiple myeloma, stage III adult Burkitt lymphoma, stage III adult Hodgkin lymphoma, stage III adult diffuse large cell lymphoma, stage III adult diffuse mixed cell lymphoma, stage III adult diffuse small cleaved cell lymphoma, stage III adult immunoblastic large cell lymphoma, stage III adult lymphoblastic lymphoma, stage III chronic lymphocytic leukemia, stage III grade 1 follicular lymphoma, stage III grade 2 follicular lymphoma, stage III grade 3 follicular lymphoma, stage III mantle cell lymphoma, stage III marginal zone lymphoma, stage III multiple myeloma, stage III small lymphocytic lymphoma, stage IV adult Burkitt lymphoma, stage IV adult Hodgkin lymphoma, stage IV adult diffuse large cell lymphoma, stage IV adult diffuse mixed cell lymphoma, stage IV adult diffuse small cleaved cell lymphoma, stage IV adult immunoblastic large cell lymphoma, stage IV adult lymphoblastic lymphoma, stage IV chronic lymphocytic leukemia, stage IV grade 1 follicular lymphoma, stage IV grade 2 follicular lymphoma, stage IV grade 3 follicular lymphoma, stage IV mantle cell lymphoma, stage IV marginal zone lymphoma, stage IV small lymphocytic lymphoma, primary myelofibrosis, Waldenstrom macroglobulinemia, adult nasal type extranodal natural killer (NK)/T-cell lymphoma, recurrent adult grade III lymphomatoid granulomatosis, childhood myelodysplastic syndromes

Eligibility Criteria

10 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

DISEASE CHARACTERISTICS:

  • Histologically confirmed diagnosis of 1 of the following:

    • Chronic lymphocytic leukemia (CLL), meeting the following criteria:

      • Absolute lymphocyte count > 5,000/mm³
      • Lymphocytes must appear morphologically mature with < 55% prolymphocytes
      • Lymphocyte phenotype with expression of CD19 and cluster of differentiation 5 (CD5)

    • Prolymphocytic leukemia (PLL), meeting the following criteria:

      • Absolute lymphocyte count > 5,000/mm³
      • More than 55% prolymphocytes
      • Morphologically diagnosed

    • Chronic myelogenous leukemia (CML), meeting the following criteria:

      • Diagnosis of CML or similar myeloproliferative disorders based on t(9;22) or related t(9;12) cytogenetic abnormalities AND characterized by elevated white blood cell (WBC) counts in peripheral blood or bone marrow
      • In first chronic phase CML and a candidate for treatment with reduced-dose busulfan
      • Patients with other cytogenetic abnormalities, such as t(9;12), that are associated with an aggressive clinical course are eligible

    • Non-Hodgkin's lymphoma (NHL), meeting the following criteria:

      • Any World Health Organization (WHO) class histologic subtype allowed
      • Core biopsies are acceptable provided they contain adequate tissue for primary diagnosis and immunophenotyping
      • Bone marrow biopsies as sole means of diagnosis are not allowed for follicular lymphoma

    • Hodgkin's lymphoma, meeting the following criteria:

      • Any WHO class histologic subtype allowed
      • Core biopsies are acceptable provided they contain adequate tissue for primary diagnosis and immunophenotyping

    • Multiple myeloma, meeting the following criteria:

      • Active disease requiring treatment (Durie-Salmon stages I, II, or III)
    • Acute myeloid leukemia with documented control, defined as < 10% bone marrow blasts and no circulating blasts

    • Acute lymphoblastic leukemia, meeting the following criteria:

      • In early first relapse or beyond OR in first complete remission and has 1 of the following high-risk features:

        • t(9;22) or t(4;11)
        • WBC count > 30,000/mm³ at presentation
        • Non-T-cell phenotype
        • More than 30 years of age

    • Agnogenic myeloid metaplasia/myelofibrosis

      • Patients who are transfusion dependent or who have evolving myelodysplastic or leukemic features or high-risk cytogenetic abnormalities are eligible
    • Myelodysplastic syndromes (MDS) as defined by WHO criteria

  • Meets 1 of the following criteria:

    • Over 55 years of age
    • Ineligible for busulfan-based therapy based on diminished organ function or poor performance status
    • Indolent and chemotherapy-responsive CLL, low-grade NHL, small lymphocytic lymphoma, or PLL
  • Patients who have undergone prior autologous stem cell transplantation are preferentially enrolled on clinical trial CALGB-100002, if available and patient is eligible

  • HLA-matched or mismatched related donor or HLA-matched unrelated donor available

    • HLA-identical sibling (6/6 or 9/10) (minimal serologic typing required for class I [A, B]; molecular typing required for class II (DRB1))
    • 9/10 matched unrelated donor (MUD) (molecular analysis at HLA A, B, C, DRB1, and DQB1 by high resolution typing required)
    • 5/6 MUD (molecular analysis at HLA A, B, and DRB1 required)
    • No syngeneic donors

PATIENT CHARACTERISTICS:

  • Creatinine clearance ≥ 40 mL/min
  • Bilirubin ≤ 3 times upper limit of normal (ULN)
  • aspartate aminotransferase (AST) ≤ 3 times ULN
  • Diffusing capacity of the lungs for carbon monoxide (DLCO) > 40% with no symptomatic pulmonary disease
  • Left ventricular ejection fraction (LVEF) ≥ 30% by multigated acquisition scan (MUGA)
  • No uncontrolled diabetes mellitus or active serious infection
  • No known hypersensitivity to Escherichia coli-derived products
  • No HIV infection
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • More than 4 weeks since prior chemotherapy, radiotherapy (except prophylactic cranial x-ray therapy), or surgery

Sites / Locations

  • Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Arm Label

Methotrexate Only Arm

2 Doses ATG + Methotrexate

2 Doses ATG

3 Doses ATG

Arm Description

GVHD Prophylaxis with Methotrexate

GVHD prophylaxis with antithymocyte globulin (ATG) + Methotrexate

GVHD prophylaxis with 2 doses ATG

GVHD prophylaxis with 3 doses ATG

Outcomes

Primary Outcome Measures

Treatment-related Mortality
Treatment related mortality for first 6 months. Defined as the number of treatment related deaths excluding deaths due to disease relapse.

Secondary Outcome Measures

Complete Response at 6 and 12 Months Post-transplant
Complete or Mixed Donor Chimerism at 30, 60, and 90 Days Post-transplant
Complete chimerism is defined as 100% donor cells detected, suggesting complete hematopoietic replacement. Mixed donor chimerism means host cells are detected in particular cells like lymphocytes. Five to 90% donor cells set the criteria for mixed chimerism (MC). Chimerism was not tabulated on day 30.
5-year Disease-free Survival
The length of time post-transplant that the patient survives without any signs or symptoms of that cancer.
Graft-vs-host Disease at 6 Months Post-transplant
Graft-vs-host disease (GVHD) can be mild, moderate or severe depending on the differences in tissue type between patient and donor. Its symptoms can include: Rashes, which include burning and redness, that erupt on the palms or soles and may spread to the trunk and eventually to the entire body Blistering, causing the exposed skin surface to flake off in severe cases Nausea, vomiting, abdominal cramps, diarrhea and loss of appetite, which can indicate that the gastrointestinal (digestive) tract is affected Jaundice, or a yellowing of the skin, which can indicate liver damage Excessive dryness of the mouth and throat, leading to ulcers Dryness of the lungs, vagina and other surfaces Acute GVHD - Can occur soon after the transplanted cells begin to appear in the recipient. Acute GVHD ranges from mild, moderate or severe, and can be life-threatening if its effects are not controlled. Extensive chronic GVHD - Usually occurs at about three months post-transplant.

Full Information

First Posted
March 14, 2007
Last Updated
May 23, 2017
Sponsor
UNC Lineberger Comprehensive Cancer Center
Collaborators
National Cancer Institute (NCI)
search

1. Study Identification

Unique Protocol Identification Number
NCT00448201
Brief Title
Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
Official Title
Allogeneic Hematopoietic Cell Transplantation for Patients With Hematologic Disorders Who Are Ineligible or Inappropriate for Treatment With a More Intensive Therapeutic Regimen
Study Type
Interventional

2. Study Status

Record Verification Date
May 2017
Overall Recruitment Status
Completed
Study Start Date
January 7, 2011 (Actual)
Primary Completion Date
January 11, 2011 (Actual)
Study Completion Date
May 23, 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
UNC Lineberger Comprehensive Cancer Center
Collaborators
National Cancer Institute (NCI)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
RATIONALE: Giving low doses of chemotherapy, such as busulfan and fludarabine, before a donor stem cell transplant helps stop the growth of cancer and abnormal cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer or abnormal cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Immunosuppressive therapy may improve bone marrow function and may be an effective treatment for hematologic cancer or other disease. PURPOSE: This clinical trial is studying the side effects and how well giving busulfan and fludarabine with or without antithymocyte globulin followed by donor stem cell transplant works in treating patients with hematologic cancer or other disease.
Detailed Description
OBJECTIVES: Primary Determine the clinical efficacy and toxicity profiles of a nonmyeloablative preparative regimen comprising busulfan and fludarabine with or without anti-thymocyte globulin followed by allogeneic hematopoietic stem cell transplantation in patients with hematologic cancers or other diseases. Determine the feasibility of this regimen in these patients. Establish a treatment-related mortality during the first 6 months that is less than 20% in patients treated with this regimen. Secondary Determine the response rates (disease-specific partial response and complete response) in patients treated with this regimen. Determine overall and progression-free survival of patients treated with this regimen. Determine the percent donor chimerism and immunologic recovery, including dendritic cell recovery, in patients treated with this regimen. Determine the risk of acute and chronic graft-versus-host disease and other toxicities in patients treated with this regimen. Assess the overall nonhematologic grades 3 and 4 toxicity of this regimen, including the incidence of veno-occlusive disease and pulmonary toxicity, in these patients. OUTLINE: Patients are assigned to 1 of 4 treatment groups according to disease type and donor type. Preparative regimen: Group 1 (patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), IPSS (International Prognostic Scoring System score) high-risk myelodysplastic syndromes (HR MDS), or chronic myelogenous leukemia (CML) with an human leukocyte antigen (HLA)-matched related donor (MRD): Patients receive fludarabine phosphate IV over 30 minutes on days -7 to -3 and busulfan IV continuously over 48 hours on days -6 and -5. Group 2 (patients with AML, ALL, IPSS HR MDS, or CML with an HLA-matched unrelated donor (MUD) or mismatched related donor (MMRD)): Patients receive fludarabine phosphate and busulfan as in group 1 and anti-thymocyte globulin IV over 4 hours on day -8. Group 3 (patients with all other diseases with a MRD): Patients receive fludarabine phosphate and busulfan as in group 1 and anti-thymocyte globulin as in group 2. Group 4 (patients with all other disease with a MUD or MMRD): Patients receive fludarabine phosphate and busulfan as in group 1 and anti-thymocyte globulin IV over 4 hours on days -8 and -7. Allogeneic stem cell transplantation: All patients undergo allogeneic peripheral blood stem cell transplantation on day 0. Patients then receive sargramostim (GM-CSF) subcutaneously once daily beginning on day 5 (groups 1 and 2) or day 7 (groups 3 and 4) and continuing until blood counts recover. Graft-vs-host disease (GVHD) prophylaxis: All patients receive oral tacrolimus twice daily on days -1 to 120 followed by a taper until day 180. Patients in groups 1 and 2 also receive methotrexate IV on days 1, 3, and 6. Donor lymphocyte infusion (DLI): After day 120, patients with progressive disease or stable disease while off immunosuppression and with no evidence of active GVHD may receive DLI. Treatment with DLI may repeat every 8 weeks for up to 3 total infusions in the absence of disease response or GVHD. Peripheral blood and/or bone marrow samples are collected at baseline and then at 30, 60, 90, 120, and 180 days post-transplantation. Chimerism (including the following subsets: whole blood, T-cells as defined by cluster of differentiation 3 (CD3) positivity, B-cells as defined by Cluster of Differentiation 19 (CD19) positivity, and myeloid cells as defined by Cluster of Differentiation 14 (CD14) and Cluster of Differentiation 15 (CD15) positivity is analyzed by polymerase chain reaction technology. After restaging between Days 90 and 100 and between Days 150 to 180, patients are followed every 6 months for 1 years and then yearly for a maximum of 5 years from study entry.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Keywords
adult acute myeloid leukemia with 11q23 (MLL) abnormalities, adult acute myeloid leukemia with inv(16)(p13;q22), adult acute myeloid leukemia with t(15;17)(q22;q12), adult acute myeloid leukemia with t(16;16)(p13;q22), adult acute myeloid leukemia with t(8;21)(q22;q22), prolymphocytic leukemia, accelerated phase chronic myelogenous leukemia, adult acute lymphoblastic leukemia in remission, adult acute myeloid leukemia in remission, blastic phase chronic myelogenous leukemia, childhood acute lymphoblastic leukemia in remission, childhood acute myeloid leukemia in remission, childhood chronic myelogenous leukemia, chronic phase chronic myelogenous leukemia, de novo myelodysplastic syndromes, extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue, nodal marginal zone B-cell lymphoma, noncontiguous stage II adult Burkitt lymphoma, noncontiguous stage II adult diffuse large cell lymphoma, noncontiguous stage II adult diffuse mixed cell lymphoma, noncontiguous stage II adult diffuse small cleaved cell lymphoma, noncontiguous stage II adult immunoblastic large cell lymphoma, noncontiguous stage II adult lymphoblastic lymphoma, noncontiguous stage II grade 1 follicular lymphoma, noncontiguous stage II grade 2 follicular lymphoma, noncontiguous stage II grade 3 follicular lymphoma, noncontiguous stage II mantle cell lymphoma, noncontiguous stage II marginal zone lymphoma, noncontiguous stage II small lymphocytic lymphoma, previously treated myelodysplastic syndromes, recurrent adult acute lymphoblastic leukemia, recurrent adult Burkitt lymphoma, recurrent adult Hodgkin lymphoma, recurrent adult diffuse large cell lymphoma, recurrent adult diffuse mixed cell lymphoma, recurrent adult diffuse small cleaved cell lymphoma, recurrent adult immunoblastic large cell lymphoma, recurrent adult lymphoblastic lymphoma, recurrent adult acute myeloid leukemia, recurrent childhood acute myeloid leukemia, recurrent/refractory childhood Hodgkin lymphoma, recurrent childhood acute lymphoblastic leukemia, recurrent childhood large cell lymphoma, recurrent childhood lymphoblastic lymphoma, recurrent childhood small noncleaved cell lymphoma, recurrent cutaneous T-cell non-Hodgkin lymphoma, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, recurrent mycosis fungoides/Sezary syndrome, recurrent small lymphocytic lymphoma, refractory chronic lymphocytic leukemia, refractory multiple myeloma, relapsing chronic myelogenous leukemia, secondary acute myeloid leukemia, secondary myelodysplastic syndromes, splenic marginal zone lymphoma, stage I multiple myeloma, stage II multiple myeloma, stage III adult Burkitt lymphoma, stage III adult Hodgkin lymphoma, stage III adult diffuse large cell lymphoma, stage III adult diffuse mixed cell lymphoma, stage III adult diffuse small cleaved cell lymphoma, stage III adult immunoblastic large cell lymphoma, stage III adult lymphoblastic lymphoma, stage III chronic lymphocytic leukemia, stage III grade 1 follicular lymphoma, stage III grade 2 follicular lymphoma, stage III grade 3 follicular lymphoma, stage III mantle cell lymphoma, stage III marginal zone lymphoma, stage III multiple myeloma, stage III small lymphocytic lymphoma, stage IV adult Burkitt lymphoma, stage IV adult Hodgkin lymphoma, stage IV adult diffuse large cell lymphoma, stage IV adult diffuse mixed cell lymphoma, stage IV adult diffuse small cleaved cell lymphoma, stage IV adult immunoblastic large cell lymphoma, stage IV adult lymphoblastic lymphoma, stage IV chronic lymphocytic leukemia, stage IV grade 1 follicular lymphoma, stage IV grade 2 follicular lymphoma, stage IV grade 3 follicular lymphoma, stage IV mantle cell lymphoma, stage IV marginal zone lymphoma, stage IV small lymphocytic lymphoma, primary myelofibrosis, Waldenstrom macroglobulinemia, adult nasal type extranodal natural killer (NK)/T-cell lymphoma, recurrent adult grade III lymphomatoid granulomatosis, childhood myelodysplastic syndromes

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
71 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Methotrexate Only Arm
Arm Type
Active Comparator
Arm Description
GVHD Prophylaxis with Methotrexate
Arm Title
2 Doses ATG + Methotrexate
Arm Type
Active Comparator
Arm Description
GVHD prophylaxis with antithymocyte globulin (ATG) + Methotrexate
Arm Title
2 Doses ATG
Arm Type
Active Comparator
Arm Description
GVHD prophylaxis with 2 doses ATG
Arm Title
3 Doses ATG
Arm Type
Active Comparator
Arm Description
GVHD prophylaxis with 3 doses ATG
Intervention Type
Biological
Intervention Name(s)
anti-thymocyte globulin
Intervention Description
0.5 mg/kg on day -3, 2.5 mg/kg on day -2 (groups 2, 3 and 4) and 3 mg/kg on day -1 (group 4 only)
Intervention Type
Biological
Intervention Name(s)
sargramostim
Intervention Description
GM-CSF 500 ug everyday (QD) subcutaneously will be given to recipients who remain with an Absolute neutrophil count (ANC) < 1000/microliter (uL) past day 20
Intervention Type
Biological
Intervention Name(s)
therapeutic allogeneic lymphocytes
Intervention Description
A minimum total cluster of differentiation 34 (CD34)+ cell dose of 3 x 10^6 cells/kg and a maximum 8 x 10^6 cells/kg will be infused on day 0
Intervention Type
Drug
Intervention Name(s)
busulfan
Intervention Description
6.4 mg/kg by continuous IV infusion over 48 hours on Days -6 and -5
Intervention Type
Drug
Intervention Name(s)
fludarabine phosphate
Intervention Description
fludarabine 30 mg/m^2/day x 5 days IV piggyback (IVPB) over 30 minutes on Days -7 through -3
Intervention Type
Drug
Intervention Name(s)
methotrexate
Intervention Description
Methotrexate 5 mg/m^2 per day on days +1, +3 and +6
Intervention Type
Drug
Intervention Name(s)
tacrolimus
Intervention Description
Suggested starting dose is 0.03 mg/kg po bid starting on Day -1
Intervention Type
Procedure
Intervention Name(s)
nonmyeloablative allogeneic hematopoietic stem cell transplantation
Intervention Description
Minimum total CD34+ cells of 3 x 10^6 cells/kg and a maximum of 8 x 10^6 cells/kg will be infused on Day 0
Intervention Type
Procedure
Intervention Name(s)
peripheral blood stem cell transplantation
Intervention Description
Minimum total CD34+ cells of 3 x 10^6 cells/kg and a maximum of 8 x 10^6 cells/kg will be infused on Day 0
Primary Outcome Measure Information:
Title
Treatment-related Mortality
Description
Treatment related mortality for first 6 months. Defined as the number of treatment related deaths excluding deaths due to disease relapse.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Complete Response at 6 and 12 Months Post-transplant
Time Frame
6 and 12 months
Title
Complete or Mixed Donor Chimerism at 30, 60, and 90 Days Post-transplant
Description
Complete chimerism is defined as 100% donor cells detected, suggesting complete hematopoietic replacement. Mixed donor chimerism means host cells are detected in particular cells like lymphocytes. Five to 90% donor cells set the criteria for mixed chimerism (MC). Chimerism was not tabulated on day 30.
Time Frame
Days 30, 60, and 90
Title
5-year Disease-free Survival
Description
The length of time post-transplant that the patient survives without any signs or symptoms of that cancer.
Time Frame
Year 5
Title
Graft-vs-host Disease at 6 Months Post-transplant
Description
Graft-vs-host disease (GVHD) can be mild, moderate or severe depending on the differences in tissue type between patient and donor. Its symptoms can include: Rashes, which include burning and redness, that erupt on the palms or soles and may spread to the trunk and eventually to the entire body Blistering, causing the exposed skin surface to flake off in severe cases Nausea, vomiting, abdominal cramps, diarrhea and loss of appetite, which can indicate that the gastrointestinal (digestive) tract is affected Jaundice, or a yellowing of the skin, which can indicate liver damage Excessive dryness of the mouth and throat, leading to ulcers Dryness of the lungs, vagina and other surfaces Acute GVHD - Can occur soon after the transplanted cells begin to appear in the recipient. Acute GVHD ranges from mild, moderate or severe, and can be life-threatening if its effects are not controlled. Extensive chronic GVHD - Usually occurs at about three months post-transplant.
Time Frame
6 Months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
10 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically confirmed diagnosis of 1 of the following: Chronic lymphocytic leukemia (CLL), meeting the following criteria: Absolute lymphocyte count > 5,000/mm³ Lymphocytes must appear morphologically mature with < 55% prolymphocytes Lymphocyte phenotype with expression of CD19 and cluster of differentiation 5 (CD5) Prolymphocytic leukemia (PLL), meeting the following criteria: Absolute lymphocyte count > 5,000/mm³ More than 55% prolymphocytes Morphologically diagnosed Chronic myelogenous leukemia (CML), meeting the following criteria: Diagnosis of CML or similar myeloproliferative disorders based on t(9;22) or related t(9;12) cytogenetic abnormalities AND characterized by elevated white blood cell (WBC) counts in peripheral blood or bone marrow In first chronic phase CML and a candidate for treatment with reduced-dose busulfan Patients with other cytogenetic abnormalities, such as t(9;12), that are associated with an aggressive clinical course are eligible Non-Hodgkin's lymphoma (NHL), meeting the following criteria: Any World Health Organization (WHO) class histologic subtype allowed Core biopsies are acceptable provided they contain adequate tissue for primary diagnosis and immunophenotyping Bone marrow biopsies as sole means of diagnosis are not allowed for follicular lymphoma Hodgkin's lymphoma, meeting the following criteria: Any WHO class histologic subtype allowed Core biopsies are acceptable provided they contain adequate tissue for primary diagnosis and immunophenotyping Multiple myeloma, meeting the following criteria: Active disease requiring treatment (Durie-Salmon stages I, II, or III) Acute myeloid leukemia with documented control, defined as < 10% bone marrow blasts and no circulating blasts Acute lymphoblastic leukemia, meeting the following criteria: In early first relapse or beyond OR in first complete remission and has 1 of the following high-risk features: t(9;22) or t(4;11) WBC count > 30,000/mm³ at presentation Non-T-cell phenotype More than 30 years of age Agnogenic myeloid metaplasia/myelofibrosis Patients who are transfusion dependent or who have evolving myelodysplastic or leukemic features or high-risk cytogenetic abnormalities are eligible Myelodysplastic syndromes (MDS) as defined by WHO criteria Meets 1 of the following criteria: Over 55 years of age Ineligible for busulfan-based therapy based on diminished organ function or poor performance status Indolent and chemotherapy-responsive CLL, low-grade NHL, small lymphocytic lymphoma, or PLL Patients who have undergone prior autologous stem cell transplantation are preferentially enrolled on clinical trial CALGB-100002, if available and patient is eligible HLA-matched or mismatched related donor or HLA-matched unrelated donor available HLA-identical sibling (6/6 or 9/10) (minimal serologic typing required for class I [A, B]; molecular typing required for class II (DRB1)) 9/10 matched unrelated donor (MUD) (molecular analysis at HLA A, B, C, DRB1, and DQB1 by high resolution typing required) 5/6 MUD (molecular analysis at HLA A, B, and DRB1 required) No syngeneic donors PATIENT CHARACTERISTICS: Creatinine clearance ≥ 40 mL/min Bilirubin ≤ 3 times upper limit of normal (ULN) aspartate aminotransferase (AST) ≤ 3 times ULN Diffusing capacity of the lungs for carbon monoxide (DLCO) > 40% with no symptomatic pulmonary disease Left ventricular ejection fraction (LVEF) ≥ 30% by multigated acquisition scan (MUGA) No uncontrolled diabetes mellitus or active serious infection No known hypersensitivity to Escherichia coli-derived products No HIV infection Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: See Disease Characteristics More than 4 weeks since prior chemotherapy, radiotherapy (except prophylactic cranial x-ray therapy), or surgery
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Thomas C. Shea, MD
Organizational Affiliation
UNC Lineberger Comprehensive Cancer Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
City
Chapel Hill
State/Province
North Carolina
ZIP/Postal Code
27599-7295
Country
United States

12. IPD Sharing Statement

Links:
URL
http://unclineberger.org
Description
University of North Carolina (UNC) Lineberger Comprehensive Cancer Center

Learn more about this trial

Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

We'll reach out to this number within 24 hrs